1. Introduction {#sec1-cancers-12-01791}
===============

The IL-1 family includes four main members, namely, IL-1α, IL-1β, IL-33, and IL-1 receptor antagonist (IL-1RA). IL-1α, IL-1β, and IL-33 are cytokine activators, while IL-1RA is an inhibitory cytokine \[[@B1-cancers-12-01791]\]. IL-1 cytokines bind the type 1 receptor (IL-1R1), except IL-33, which binds IL-1R4 (ST2). While IL-1α or IL-1β fixation on IL-1R1 induces a downstream signaling cascade and the transcription of several genes involved in inflammatory and immune pathways, IL-RA fixation does not have the same effect \[[@B2-cancers-12-01791]\].

IL-1α and IL-1β are encoded by two different genes, with a low degree of sequence homology. They are both synthesized as preform proteins, pro-IL-1α and pro-IL-1β. Pro-IL-1β needs to be converted into IL-1β (by inflammatory caspase cleavage) to be active, whereas pro-IL-1α is active, and its cleavage into IL-1α (by calpain) will modulate its activity \[[@B3-cancers-12-01791]\]. IL-1α can be localized in the nucleus, where it acts as a transcription factor to regulate cell differentiation in normal cells, as well as neoplasia in cancer cells. However, when cells undergo cell death, such as necrosis, IL-1α translocates into the cytosol and is released into the extracellular space to act as an « alarmin » \[[@B3-cancers-12-01791],[@B4-cancers-12-01791]\]. In contrast, the synthesis and processing of IL-1β are tightly controlled and require two signals, namely "priming" to allow transcription of the IL1B gene and the activation signal, which leads to activation of inflammasome complexes and inflammatory caspases to cleave pro-IL-1β into mature IL-1β \[[@B5-cancers-12-01791]\].

Although IL-1β and IL-1α share similar transducing pathways, they have different expression and activation processes, explaining why they have different biological and physiological effects in many diseases, notably cancer.

1.1. IL-1β Production {#sec1dot1-cancers-12-01791}
---------------------

Within the tumor, IL-1β is produced and secreted by various cell types, such as immune cells, fibroblasts, or cancer cells. However, the mechanisms of IL-1β production have been most widely studied in immune cells, particularly in myeloid cells, such as macrophages. As mentioned above, IL-1β production requires two signals, namely "priming" and cleavage ([Figure 1](#cancers-12-01791-f001){ref-type="fig"}).

### 1.1.1. "Priming" {#sec1dot1dot1-cancers-12-01791}

"Priming" corresponds to the transcription of the Il1b/IL1B gene, and is induced mainly by activation of the toll-like-receptors (TLRs), namely lipopolysaccharides (LPS), but also by tumor necrosis factor (TNF) α, through the TNF receptor or IL-1β itself ([Figure 1](#cancers-12-01791-f001){ref-type="fig"}). TLRs and IL-1R1 recruit the same adaptor protein, myeloid differentiation primary response 88 (Myd88), through their intra-cellular domain, which in turn activates interleukin-1 receptor-associated kinase 1/4 (IRAK1/4) and the TNFR-associated factor 6 (TRAF6) pathway. TNFR recruits TNFR1-associated death domain (TRADD), which activates the TRAF2/5 and receptor interacting protein 1 (RIP1) pathway. All these signaling cascades are able to activate nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB) \[[@B6-cancers-12-01791],[@B7-cancers-12-01791]\]. As hypoxia is an important event within the tumor, hypoxia-induced factor 1 (HIF1) was shown to regulate Il1b/IL1B transcription. Other classical transcription factors were also shown to induce Il1b/IL1B expression in myeloid cells, such as CCAAT/enhancer binding protein (C/EBP-)β, Interferon response factors 4 or 8 (IRF4/8) and PU.1 or protein kinase C (PKC)/activator protein-1 (AP-1), directly or through Myd88 \[[@B6-cancers-12-01791]\]. The STAT1 pathway was also shown to be required in macrophages to enable IL-1β production \[[@B8-cancers-12-01791]\]. Finally, single nucleotide polymorphisms (SNPs) in the Il1b/IL1B gene or promoter can affect Il1b/IL1B transcription by inhibiting the fixation of the transcription factors described above or by allowing the fixation of repressor factors.

After transcription/translation, pro-IL-1β is produced as an inactive, 31kDa protein that needs to be cleaved into 17kDa IL-1β to become active.

### 1.1.2. Inflammasomes {#sec1dot1dot2-cancers-12-01791}

To be activated, pro-IL-1β needs to be cleaved by proteases. Although cleavage by cathepsin G or elastase in neutrophils has been described, yielding low-activity IL-1β, caspases are the main proteases that can provide fully-active IL-1β. Caspase-8 has been shown to cleave IL-1β in vitro and in specific conditions. However, the most important enzyme involved in IL-1β maturation remains caspase-1, which has been reported to be activated via numerous sources \[[@B9-cancers-12-01791]\].

Caspase-1 activation occurs via recruitment to multi-protein complexes called inflammasomes. These intracellular complexes are all composed of a receptor and an adaptor, allowing recruitment and activation of pro-inflammatory caspases \[[@B5-cancers-12-01791]\].

The receptors, called nucleotide-binding oligomerization domain-containing protein (Nod)-like receptors (or NLR), recognize a wide variety of stimuli referred to as pathogen-associated molecular patterns (PAMPs) ([Figure 1](#cancers-12-01791-f001){ref-type="fig"}). The NLR family is characterized by the presence of several specific domains. All of these proteins have a central NACHT ((NAIP (neuronal apoptosis inhibitor protein), C2TA (MHC (major histocompatibility complex) class 2 transcription activator), HET-E (incompatibility locus protein from Podospora anserina), and TP1 (telomerase-associated protein)) domain, responsible for complex activation, via ATP-dependent oligomerization. At the C-terminal, the leucine-rich domain (LRR) is involved in ligand detection and in complex self-regulation. The N-terminal is either a pyrin domain (PYD) or a caspase recruitment domain (CARD) involved in protein--protein interactions for signal transduction. Thus, activated receptors can recruit either pro-caspases (via the CARD) or an adaptor protein (via the PYD), which in turn will recruit a pro-caspase. The NLR receptors are divided into four families, with many members, according to the N-terminal domain composition. However, the NOD-LRR and pyrin containing protein 3 (NLRP3) is the most important receptor, and is responsible for caspase-1 activation under sterile conditions \[[@B5-cancers-12-01791],[@B10-cancers-12-01791]\].

Prior to its activation, the expression of NLRP3 is under the control of NF-κB activation, like IL-1β. NLRP3 is activated by a wide variety of stimuli and by three non-exclusive pathways, with possible crosstalk. The first is intracellular K^+^ efflux induced by binding of extra-cellular ATP to its receptor P2X7. The second involves phagocytosis of crystalline structures and subsequent lysosome damage. Lysosomal content, especially cathepsin B, will then activate NLRP3 through direct interaction. The third pathway involves an increase in reactive oxygen species (ROS) synthesis. All these steps will converge to NLRP3 activation, recruitment of ASC (apoptosis associated speck-like protein containing a CARD domain) and pro-caspase-1, and IL-1β and IL-18 maturation \[[@B11-cancers-12-01791],[@B12-cancers-12-01791]\].

### 1.1.3. Secretion {#sec1dot1dot3-cancers-12-01791}

The mechanisms that lead to IL-1β secretion are not clear ([Figure 1](#cancers-12-01791-f001){ref-type="fig"}). This might be explained by the existence of several pathways that may or may not co-exist, depending on the context ([Figure 1](#cancers-12-01791-f001){ref-type="fig"}). Studies of IL-1β secretion used different experimental settings, such as in vivo, ex vivo, or in vitro cultures; different cellular models (primary cells, cell lines) and cell types (macrophages, fibroblasts, neutrophils); several activators that induce cell death or not (pyroptosis, necrosis); as well as different techniques to detect IL-1β (ELISA, Western blot, IL-1 HEK-blue cells). Moreover, techniques used to investigate IL-1β secretion pathways, such as electronic microscopy, immunofluorescence, or the use of more or less specific inhibitors of intra-cellular traffic, only give clues and not a real explanation. Actually, analyses are made on single cells at a specific time point and may make impossible to determine whether one or two mechanisms co-exist. In general, IL-1β is released through vesicles (autophagolysosomes, microvesicles, or exosomes) or through membrane permeability (gasdermin D (GSDMD) pores, membrane rupture).

Pro-IL-1β and IL-1β are localized in the cytoplasm and a fraction is sequestered in vesicles identified as endosomes/lysosomes, via an unidentified mechanism. A part of lysosomal IL-1β is targeted for degradation, while a fraction is saved for further exocytosis and secretion, through fusion with the plasma membrane \[[@B13-cancers-12-01791],[@B14-cancers-12-01791]\]. However, IL-1β may be protected from the acidic pH of lysosome, to avoid its degradation. This rescue is enabled thanks to autophagy, a process that encapsules damaged organelles or proteins in a double membrane structure called autophagosome. Autophagosomes generally fuse with lysosomes to proteotically degrade their content. In this context, it has been reported that IL-1β can localize between the two layers of autophagosomes, possibly explaining why IL-1β is not degraded \[[@B15-cancers-12-01791]\]. Autophagosomes can also fuse with IL-1β-containing endosomes to undergo exocytosis and IL-1β release out of the cell \[[@B13-cancers-12-01791],[@B14-cancers-12-01791]\]. Multi vesicular bodies containing IL-1β (but also caspase-1 and inflammasome components) can fuse with lysosomes for degradation of their content or with plasma membrane to form and release exosomes \[[@B16-cancers-12-01791]\].

Once cleaved, IL-1β exhibits an overall positive charge to enable it to colocalize with negatively charged phosphatidylinositol 4,5-bisphosphate (PIP2) in the plasma membrane. Then, shedding of microvesicles from plasma membranes makes it possible for IL-1β to be released out of the cell \[[@B17-cancers-12-01791]\].

As well as cleaving pro-IL-1β, activated caspase-1 can also trigger a type of inflammatory cell death called pyroptosis. This type of cell death is characterized by inflammatory caspase activation (caspase-1 and/or caspase-11/4/5) and LDH (lactate dehydrogenase) release through membrane permeabilization. This latter event was recently shown to be mediated by gasdermin D (GSDMD) cleavage. Once cleaved by caspase-1, -11, or -5, the N-terminal fragment of GSDMD oligomerizes into ring-shaped structures to form membrane pores. These pores enable the exit of mature IL-1β (the proform being too big). They also allow the entry of sodium and water. If the activation signal and the number of GSDMD pores are low, membrane fusion can patch the pores. On the contrary, if the signal and the number of GSDMD pores are high, the sodium and water entry will induce membrane rupture, allowing the release of the cytosolic content such as pro-IL-1β and IL-1β. However, pro-IL-1β release is not without consequence if extra-cellular proteases cleave it into mature form \[[@B18-cancers-12-01791],[@B19-cancers-12-01791]\].

The release of IL-1β and its preform pro-IL-1β into vesicles raises questions about its stability and detection. Actually, IL-1β has a very short half-life \[[@B20-cancers-12-01791]\] and its packaging into vesicles can allow it to resist degradation and act at sites distant from the production site. As IL-1β can be encapsulated into vesicles, and pro-IL-1β can be found in the supernatant, the detection of active IL-1β by classical methods such as ELISA can be compromised \[[@B21-cancers-12-01791],[@B22-cancers-12-01791],[@B23-cancers-12-01791]\]. To confirm the presence of mature IL-1β, complementary methods, such Western blot on cell supernatants or HEK-blue cells, to detect active IL-1β should be used. However, the incapacity to detect IL-1β would not assure its absence.

1.2. IL-1β Signaling {#sec1dot2-cancers-12-01791}
--------------------

IL-1β binds to IL-1R, which belongs to the superfamily of TLR/IL-1R, characterized by the presence of an intra-cellular TIR (TLR/IL-1R) domain ([Figure 1](#cancers-12-01791-f001){ref-type="fig"}). More particularly, IL-1β can bind to IL-1R1 and IL-1R2, which present three extra-cellular Ig binding domains and are associated with the highly homologous IL-1R accessory protein (IL-1RAcP or IL-1R3). However, the transmission of a signal after IL-1β binding to its receptors is not a simple matter. In fact, IL-1R2 has no TIR domain and acts as a decoy receptor. Moreover, IL-1RA can also bind IL-1R1 without inducing an activator signal, taking the place of IL-1β \[[@B6-cancers-12-01791],[@B24-cancers-12-01791]\]. Thus, only IL-1β/IL-1R1/IL-1RAcp will enable transmission of a signal. This raises the question not only of the amount of IL-1β produced, but also of the level of IL-1Rs expression on target cells and the level of IL-1RA.

Once activated, IL-1R/IL1-RAcP can recruit Myd88 through TIR domains present in the intra-cellular domain of IL-1R and on the C-terminal domain of Myd88. Then, MyD88 associates with IRAK 4, IRAK1, and/or IRAK2. IRAK4 in turn phosphorylates IRAK1 and IRAK2 to enable their association with TRAF6. TRAF6 serves as a platform to recruit and activate the transforming growth factor β-activated kinase 1 (TAK1). TAK1 will activate either p38 and JNK (c-Jun N-terminal kinase), leading to activation of transcription factor AP-1, or the IKK (inhibitor of NF-*κ*B kinase) complex, composed of IKKα, IKKβ, and IKKγ. The IKK complex catalyzes phosphorylation and subsequent degradation of IκB, rendering NF-κB (i.e., p50/p65) free to translocate from the cytosol to the nucleus and to activate NF-κB-dependent genes \[[@B25-cancers-12-01791]\].

The activation of p38/JNK and NF-κB leads to the transcription of target genes involved in several biological processes, depending on the cell type stimulated by IL-1β.

2. IL-1β as a Cancer Marker? {#sec2-cancers-12-01791}
============================

The importance of IL-1β can first be considered by its impact on cancer development or progression. This evaluation can be performed by quantifying IL1B mRNA or IL-1β protein expression or by measuring gene polymorphisms that may influence its expression ([Table 1](#cancers-12-01791-t001){ref-type="table"}).

Using the cancer genome atlas (TCGA) database, breast cancer patients with high levels of mRNA expression of IL1B were shown to have a better prognosis than those with low levels \[[@B30-cancers-12-01791]\]. Similarly, the quantification of IL1B mRNA by qPCR in cervical cancer biopsies showed an increase in the risk of progression of pre-neoplasic lesions in women with lower IL1B expression \[[@B31-cancers-12-01791]\]. On the contrary, TCGA analysis on glioma patient samples shows that high expression of "IL1B-signature" is correlated with high expression of CD133 (a marker of glioma aggressiveness) and associated with poor prognosis \[[@B32-cancers-12-01791]\]. These discrepancies might be explained by the fact that mRNA expression was studied at a single time point and that these analyses did not consider the patient's cancer stage, or whether they had received treatment. Moreover, IL1B mRNA expression cannot predict its maturation by inflammasomes.

In this concept, immunohistochemical analyses showed that upregulation of ASC, caspase-1, IL-1β, AIM2, RIG-I, and NLRP3 expression correlated with better local recurrence-free survival and disease-free survival of nasopharyngeal carcinoma patients \[[@B26-cancers-12-01791]\]. Again, this increased expression does not reflect IL-1β activity.

Finally, IL-1β levels can be measured in patient plasma or serum by ELISA. IL-1β is significantly overexpressed both at mRNA and protein levels in gastro-esophageal cancer or squamous cell carcinoma samples compared with mucosa from controls \[[@B56-cancers-12-01791],[@B57-cancers-12-01791],[@B58-cancers-12-01791]\]. High IL-1β levels are associated with shorter overall and progression-free survival for non-small cell lung cancer (NSCLC) patients treated with platinum-based combination chemotherapy or with chemotherapy/bortezomib and for pancreatic cancer patients treated with gemcitabine \[[@B27-cancers-12-01791],[@B28-cancers-12-01791],[@B29-cancers-12-01791]\].

Polymorphisms on the IL1B gene can be associated with variation in IL-1β expression. For example, *IL1B-511 C \> T* (rs16944) and *IL-1β-31 C \> T* (rs1143627) T alleles are associated with an increase in IL-1β serum concentration in cervical and gastric cancer patients \[[@B59-cancers-12-01791],[@B60-cancers-12-01791],[@B61-cancers-12-01791]\], or in the supernatant of cells harboring rs1143627 \[[@B62-cancers-12-01791]\]. Conflicting results were obtained concerning *IL1B-511* (rs16944) homozygote C/C genotypes, suggesting a low expression of IL1B. In one study, it was associated with the risk of ovarian cancer, while in two others, it was not \[[@B33-cancers-12-01791],[@B34-cancers-12-01791],[@B35-cancers-12-01791]\]. Similarly, C/C genotypes may or may not be associated with a higher risk of lung cancer, depending on the studies \[[@B36-cancers-12-01791],[@B37-cancers-12-01791]\]. *IL1B-511T* carriers, suggesting higher expression of IL1B, present a higher risk of developing gastric cancer \[[@B38-cancers-12-01791],[@B39-cancers-12-01791],[@B40-cancers-12-01791],[@B41-cancers-12-01791],[@B42-cancers-12-01791],[@B43-cancers-12-01791],[@B44-cancers-12-01791],[@B45-cancers-12-01791]\], or not \[[@B46-cancers-12-01791]\]. *IL1B-511T* carriers present a higher risk of developing cervical cancer, acute myeloid leukemia, or chronic myeloid leukemia \[[@B47-cancers-12-01791],[@B48-cancers-12-01791],[@B49-cancers-12-01791],[@B50-cancers-12-01791]\]. Concerning breast cancer, no association was shown between *IL1B-511* (rs16944) and the risk of breast cancer development \[[@B63-cancers-12-01791]\]. *IL-1β-31* (rs1143627) T allele is associated with an increased IL1B expression. The T/T genotype was associated with a higher risk of breast cancer \[[@B51-cancers-12-01791],[@B52-cancers-12-01791]\], lung cancer \[[@B36-cancers-12-01791],[@B37-cancers-12-01791]\], cervical cancer \[[@B48-cancers-12-01791]\], hepatocellular carcinoma \[[@B53-cancers-12-01791]\], or osteosarcoma \[[@B54-cancers-12-01791]\] in various studies. On the contrary, C allele carriers have a higher risk of developing gastric cancer \[[@B45-cancers-12-01791]\]. For *IL-1β-1464 G \> C* (rs1143623), the G allele has decreased binding ability, suggesting weaker promoter activity \[[@B64-cancers-12-01791]\]. It is associated with renal cell carcinoma \[[@B55-cancers-12-01791]\].

With all these results, it is difficult to certify whether IL-1β expression or IL1B polymorphisms can predict the outcome of cancer patients.

3. Pro-and Anti-Tumor Effects of IL-1β {#sec3-cancers-12-01791}
======================================

IL-1β has been shown to play a role in many physiological events. It can modulate gene expression and cytokine production, regulating cellular adhesion and migration, angiogenesis, or immune response. However, the repercussions on the course of cancer are complex, and both positive and negative functions of IL-1β have been described. These observed discrepancies make IL-1β a possible target that may need to be taken in consideration, depending on the cancer type and the anti-tumor treatments.

3.1. IL-1β Effects on Cancer Occurrence {#sec3dot1-cancers-12-01791}
---------------------------------------

IL-1β has been shown to be upregulated in many solid tumors, including melanoma, colon, lung, breast, or head and neck cancers and is associated with poorer prognosis. While its role in carcinogenesis is well described for some cancer types, its implication in other types is not as well elucidated.

### 3.1.1. Skin Cancers {#sec3dot1dot1-cancers-12-01791}

NLRP1 gain-of-function mutations are responsible for constitutive secretion of IL-1β by keratinocytes, which enable skin inflammation and epidermal hyperplasia, and a predisposition to skin cancer \[[@B65-cancers-12-01791]\]. Human metastatic melanoma samples and human cell lines were described to constituvely express and secrete IL-1β \[[@B66-cancers-12-01791]\]. Using B16 melanoma or 3-methylcholanthrene (3-MCA)-induced skin cancer models, it has been shown that the incidence of tumor development in mice was impaired in IL-1β-deficient or in IL-RA-treated animals \[[@B67-cancers-12-01791],[@B68-cancers-12-01791]\]. On the contrary, the incidence of mice-bearing tumors was improved in IL-1RA-deficient animals \[[@B68-cancers-12-01791]\]. In contrast, another study showed in the B16-F10 model that blocking IL-1β with an antibody increased tumor appearance in wild type (WT) mice, thus suggesting that IL-1β was protective in this context \[[@B69-cancers-12-01791]\].

### 3.1.2. Colon Cancer {#sec3dot1dot2-cancers-12-01791}

High amounts of IL-1β and IL-1α were detected in a murine adenomatous polyposis coli (APC) colon cancer model \[[@B70-cancers-12-01791]\]. Contrasting effects of IL-1β have been described on colon cancer incidence. This may partly be because of the use of mice deficient in NLRP3 inflammasome components, which are responsible not only for IL-1β production, but also for IL-18 production \[[@B71-cancers-12-01791],[@B72-cancers-12-01791],[@B73-cancers-12-01791]\]. Another possible explanation is that IL-1β targets several cell types. Using disruption of IL1-R1 on different cell types in a mouse model, it was recently shown that IL-1R1 deficiency in epithelial cells reduces tumorigenesis in an APC model, while IL1-R1 deficiency in neutrophils increases bacterial invasion and tumor aggressiveness \[[@B70-cancers-12-01791]\]. This study proposed dichotomous effects of IL-1, without differentiating between IL-1β and IL-1α.

In vitro, IL-1β was shown to upregulate miR-181a expression in human colon cancer cells, through NF-κB, which is responsible for phosphatase and tensin homolog (PTEN) repression and cell proliferation induction \[[@B74-cancers-12-01791]\]. A similar effect of IL-1β on colon cancer cell proliferation was shown via inactivation of glycogen synthase kinase (GSK)3β, leading to activation of the Wnt pathway and tumor growth \[[@B8-cancers-12-01791]\].

### 3.1.3. Lung Cancer {#sec3dot1dot3-cancers-12-01791}

The level of IL-1β in bronchoalveolar lavage is higher in patients with lung cancer than in patients with benign lung disease \[[@B75-cancers-12-01791]\]. IL-1β was shown to promote carcinoma by repressing miR-101 expression through a cyclooxygenase 2 (COX2)/HIF1α pathway. MiR-101 inhibits malignant transformation and cancer progression by negatively regulating oncogene expression. Thus, IL-1β/miR-101 is a new regulatory axis of pathogenic inflammatory signaling in NSCLC \[[@B76-cancers-12-01791]\].

### 3.1.4. Breast Cancer {#sec3dot1dot4-cancers-12-01791}

It has long been established that there is IL-1β protein expression within human breast tumor samples \[[@B77-cancers-12-01791]\]. Moreover, IL-1β is upregulated in breast neoplasm initiation and development \[[@B78-cancers-12-01791]\], while IL-1R and IL-1β variations have also been related to breast tumorigenesis \[[@B79-cancers-12-01791]\]. One possible explanation is that IL-1β increases IL-6 production through a transglutaminase 2/NF-κB pathway. This leads to an increase in luminal-type breast cancer cell aggressiveness. This can be inhibited using an anti- IL-1β or an anti-IL-6 \[[@B80-cancers-12-01791]\]. Another pathway has been described, using the fibroblast growth factor receptor 1 (FGFR1)-induced murine mammary carcinoma model. It implicates IL-1β-mediated expression of COX-2, which is responsible for early-stage mammary lesions \[[@B81-cancers-12-01791]\]. The potential utility of inhibiting IL-1β was underlined by studies using deficient mice or anti-IL-1 antibody, suggesting that IL-1β in the tumor environment contributes to breast tumor progression \[[@B82-cancers-12-01791],[@B83-cancers-12-01791]\].

### 3.1.5. Gastric Cancer {#sec3dot1dot5-cancers-12-01791}

The use of a human IL-1β fused to a signal peptide to specifically induce its expression in mouse stomach epithelial cells led to the development of spontaneous gastric inflammation; pre-neoplastic lesions; and, in some cases, tumors, suggesting an initiator role of IL-1β \[[@B84-cancers-12-01791]\]. Moreover, in gastric cells infected with *Helicobacter pylori,* yes-associated protein 1 (YAP1) displays nuclear translocation and works with TEAD to activate transcription of IL1B. The IL-1β thus produced displays YAP1-mediated cell proliferation \[[@B85-cancers-12-01791]\]. To transduce this proliferating signal, IL-1β may bind to its receptor and activate NF-κB, which initiates JNK signaling, causing gastric cancer development \[[@B74-cancers-12-01791],[@B86-cancers-12-01791],[@B87-cancers-12-01791]\].

### 3.1.6. Oral Cancers {#sec3dot1dot6-cancers-12-01791}

Salivary IL-1β was described to be significantly higher in oral cancer patients than in a control group \[[@B88-cancers-12-01791]\]. In oral squamous cell carcinoma, IL1B is overexpressed in tumors as compared with non-tumor matched samples. In mice, induction of oral malignancy by 4-Nitroquinolin-1-oxide (4-NQO) and arecoline triggers pro-IL-1β expression, which is proportional to cancer severity \[[@B89-cancers-12-01791]\].

### 3.1.7. Pancreatic Cancer {#sec3dot1dot7-cancers-12-01791}

In human pancreatic ductal adenocarcinoma (PDAC) samples, high stromal IL-1β expression is associated with poor overall survival of patients \[[@B90-cancers-12-01791]\]. In mice, IL-1β involvement in cancer incidence was addressed, using IL-1β expression specifically in the pancreas, via the elastase promoter. While the expression of IL-1β resulted in chronic pancreatitis, mice only developed acinal-ductal metaplasia \[[@B91-cancers-12-01791]\]. Perhaps the use of a carcinogen inductor, such as dimethylbenzanthracene, would make it possible to prove the importance of IL-1β in the appearance of pancreatic carcinoma.

Further studies are warranted to elucidate these observed discrepancies. Differences might be because of the means used to invalidate IL-1β, that is, KO mice with no IL-1β in the host, but with tumor cells producing IL-1β, or neutralizing antibody with a decrease, but not inhibition of both host and tumor IL-1β.

### 3.1.8. Ovarian Cancer {#sec3dot1dot8-cancers-12-01791}

Urinary and serum levels of IL-1β tend to be more elevated in patients with epithelial ovarian cancer than in healthy women \[[@B92-cancers-12-01791]\]. In the 2780 ovarian cancer cell line, IL-1β induces the expression of matrix metalloproteinase (MMP)8, a factor implicated in cancer progression \[[@B93-cancers-12-01791]\].

### 3.1.9. Prostate Cancer {#sec3dot1dot9-cancers-12-01791}

High-score values for IL-1β or low-score values for interferon (IFN)β (both measured by immunohistochemistry (IHC)) were significantly associated with biochemical recurrence of prostate cancer \[[@B94-cancers-12-01791]\]. Moreover, IL-1β and IL-1R2 (the decoy receptor) high expression and IL-1R1 low expression are associated with higher progression free survival (PFS) \[[@B95-cancers-12-01791]\].

In vitro monocytic-derived IL-1β inhibits LNCaP prostate cancer proliferation or induces apoptosis \[[@B96-cancers-12-01791],[@B97-cancers-12-01791],[@B98-cancers-12-01791]\]. Moreover, IL-1β resistant LNCaP cells (obtained after long exposure to IL-1β) become resistant to many chemotherapeutic drugs and have a more important capacity to develop tumors in mice \[[@B98-cancers-12-01791]\]. IL-1β has an antiproliferative effect on prostate cancer cells, enhanced by coculture with normal fibroblasts, through IL-6 \[[@B99-cancers-12-01791]\]. Mechanistically, IL-1β can induce prostate tumor progression by several pathways. Through NF-κB, IL-1β induces the activation of epithelium-specific ETS (E26 transformation-specific) ESE1 (or E74-like factor (ELF3)), two ETS family members responsible for prostate cancer malignancy and associated with a poor prognosis for patients \[[@B100-cancers-12-01791]\]. IL-1β can also induce the expression of endothelin 1 (ET-1), which is implicated in prostate tumor progression \[[@B101-cancers-12-01791]\]. Finally, IL-1β induces the expression of matrisylin in human LNCaP prostate cancer cells, a metalloprotease involved in cancer progression \[[@B102-cancers-12-01791]\].

Androgen inhibition belongs to the therapeutic arsenal to treat prostate androgen receptor (AR) positive cancers. It has been shown that IL-1β decreases AR expression, which may interfere with anti-androgen therapies' efficiency \[[@B93-cancers-12-01791],[@B103-cancers-12-01791],[@B104-cancers-12-01791]\]. An amplification loop may exist, as AR^-^ cancers cells express high levels of IL-1β, while AR^+^ cells do not and androgen-deprivation drugs, that is, leuprolide and bicalutamide, inhibit prostate cancer cells' mediated IL-1β secretion by peripheral blood mononuclear cells (PBMC) in vitro \[[@B105-cancers-12-01791],[@B106-cancers-12-01791]\].

### 3.1.10. Mutational Status {#sec3dot1dot10-cancers-12-01791}

In addition to cancer types, IL-1β can affect or can be affected by common cancer-associated mutations.

In acute lymphoblastic leukemia, KRAS (Kirsten rat sarcoma viral oncogene homolog) G12D mutation is responsible for the binding of cAMP response element binding (CREB) on IL1B promoter and increases the expression of IL-1β in these cells \[[@B107-cancers-12-01791]\]. KRAS G12D expression in murine bone-marrow cells leads to NLRP3 inflammasome activation and IL-1β expression and to myeloproliferation. IL-1RA or NLRP3 inhibition reverses the effects of KRAS mutation on myeloproliferation \[[@B108-cancers-12-01791]\]. Moreover, overexpression of IL-1β in KRAS G12D mutant mice accelerates the development of PDAC through autocrine activation of IL-1R1-mediated epithelial cell proliferation and an increased level of immunosuppressive PD-L1^+^ B-cells \[[@B109-cancers-12-01791]\]. This finding is correlated with the fact that myeloid-derived IL-1β induces NF-κB activation more importantly in KRAS mutant (G12C or G13R) cancer cells than in WT cells, leading to drug resistance \[[@B110-cancers-12-01791]\]. Thus, an amplification loop between IL-1β and mutated-KRAS seems to increase cancer progression and drug resistance.

Expression of mutated BRAF (v-raf murine sarcoma viral oncogene homolog B1) V600E mutation induces the transcription of IL1A and IL1B in papillary thyroid carcinoma cells, melanocytes, and melanoma cell lines and this induction can be inhibited by vemurafenib \[[@B111-cancers-12-01791],[@B112-cancers-12-01791],[@B113-cancers-12-01791]\]. On the contrary, this BRAF(V600E) inhibitor increases DC-mediated IL-1β production \[[@B114-cancers-12-01791]\]. However, the impact of BRAF(V600E) on IL-1β production and cancer evolution remains to be studied.

IL-1β treatment leads to a decreased PTEN expression, PI3K/AKT signaling activation, and to the induction of epithelial to mesenchymal transition (EMT) in NSCLC cells \[[@B115-cancers-12-01791]\]. IL-1β induces the expression of miR-425, miR-181a, and miR-181b through NF-κB, in gastric cancer, colon cancer, and osteosarcoma cells, respectively. These miRNA repress PTEN expression, leading to apoptosis inhibition and proliferation-associated cancer cell growth \[[@B74-cancers-12-01791],[@B116-cancers-12-01791],[@B117-cancers-12-01791]\]. PTEN expression in myeloid cells dictates NLRP3 inflammasome activation and IL-1β expression. Then, it allows mitoxanthrone anti-cancer activity in MC0205 fibrosarcoma model in mice. Moreover, in breast cancer patients, PTEN expression is correlated with IL-1β expression and to anthracyclines-based adjuvant chemotherapy sensitivity \[[@B118-cancers-12-01791]\].

Ovarian cancer cells communicate with cancer-associated fibroblasts (CAFs) through IL-1β to downregulate p53 expression in these cells to generate a pro-tumorigenic inflammatory microenvironment \[[@B119-cancers-12-01791]\]. Similarly, downregulation of IL-1β, IL1-R1, or Myd88 increases p21 and p53 in human melanoma cells \[[@B120-cancers-12-01791]\]. On the contrary, the p53 status seems to regulate IL-1β response. WT p53 increases IL-1RA expression, which represses colon and breast cancer cells proliferation in vitro and tumor growth in vivo, while mutant p53 represses IL-1RA expression, allowing IL-1β effects \[[@B121-cancers-12-01791]\]. Wnt secretion by p53-deficient breast cancer cells activates IL-1β production by macrophages. IL-1β then activates neutrophils to dampen CD8-mediated anti-tumor immune response \[[@B122-cancers-12-01791]\].

P73 and, more particularly, Tap73, a constitutively active p73, is able to increase the transcription of IL1B and CASP1 in lung and breast cancer cells, allowing these cells to produce IL-1β \[[@B123-cancers-12-01791]\]. The impact on cancer has to be defined.

BRCA1 (breast cancer 1) 185delAG mutation in ovarian epithelial cells allows IL-1β expression \[[@B124-cancers-12-01791]\]. BRCA1 helps the sensing of herpes virus DNA and the activation of caspase-1 and IL-1β production \[[@B125-cancers-12-01791]\]. However, the consequences of IL-1β in WT or mutated BRCA1 on cancer initiation or progression remain to be investigated.

3.2. IL-1β Effects on Tumor Immune Response {#sec3dot2-cancers-12-01791}
-------------------------------------------

As seen below, the fact that IL-1β can be produced endogenously and/or by cancer cells highlights the importance of the microenvironment, and more particularly immune cells, in IL-1β-mediated effects ([Figure 2](#cancers-12-01791-f002){ref-type="fig"}).

### 3.2.1. Myeloid-Derived Suppressor Cells (MDSCs) {#sec3dot2dot1-cancers-12-01791}

MDSCs form a population of immature myeloid cells with the ability to dampen T-cell activation \[[@B126-cancers-12-01791]\]. These cells have been shown to markedly expand in lymphoid organs and blood in tumor-bearing mice \[[@B84-cancers-12-01791]\]. In addition, the frequency of MDSCs is increased in the blood of patients with different types of cancers \[[@B127-cancers-12-01791],[@B128-cancers-12-01791]\]. In mice and humans, MDSCs are one of the major suppressors of antitumor immunity, mainly by inducing antigen-specific MHC class I restricted tolerance of CD8^+^ T-cells \[[@B129-cancers-12-01791]\].

The importance of IL-1 in MDSC accumulation came from a study showing that tumor bearing IL-1R1-deficient mice presented decreased tumor growth and fewer MDSCs \[[@B130-cancers-12-01791]\]. However, this work did not discriminate the effects of IL-1α and IL-1β.

Overexpression of IL-1β in gastric cancer or fibrosarcoma models leads to accumulation of MDSCs at the tumor site. The inhibition of IL-1, using IL-1RA, decreases or suppresses MDSC accumulation at the tumor site and inhibits tumor development in these models \[[@B84-cancers-12-01791],[@B131-cancers-12-01791]\].

Overexpression of IL-1β in mammary 4T1 tumor cells can modify MDSC phenotype (more CD8, CD80, CD83, and CD14 expression and lower CD44 and B220) in vivo, while it does not change their capacity to dampen CD4 and CD8 T-cells' activation/proliferation \[[@B132-cancers-12-01791]\]. This suggests that the effect of IL-1β relies more on the accumulation of MDSCs than on increased immunosuppressive activity. An effect of IL-1β on the different subtypes of MDSCs has been observed. In the mammary 4T1 tumor model, overexpression of IL-1β (in the tumor or the host) or the invalidation of IL-1RA led to an accumulation of Ly6C negative MDSCs, that is, polymorphonuclear (PMN)-MDSCs, whereas blocking IL-1β decreases the number of MDSCs. The consequences of high IL-1β expression are a decrease in functional natural killer (NK) cells and increased tumor growth \[[@B133-cancers-12-01791]\]. However, the direct effect of IL-1β on MDSCs was not studied in this work. It was shown that MDSCs from mammary 4T1 tumors do not express IL-1R1 \[[@B132-cancers-12-01791]\], suggesting that these cells cannot respond directly to IL-1β.

IL-1β-induced inflammation increases IL-10 production by MDSCs and activates MDSCs, which are more effective at down-regulating macrophage production of IL-12 as compared with MDSCs isolated from less-inflammatory tumor microenvironments \[[@B134-cancers-12-01791]\].

### 3.2.2. Macrophages {#sec3dot2dot2-cancers-12-01791}

Tumor-associated macrophages (TAMs) compose a heterogeneous family that may be classically divided into M1 and M2 macrophages. This classification is based on the capacity of M1 to produce nitric oxide synthase/IL-12/TNF-α and to promote Th1 responses, while M2 produce arginase-1/IL-10/TGF-β to support Th2-associated effector functions \[[@B135-cancers-12-01791],[@B136-cancers-12-01791]\]. However, a spectrum of polarization exists in the tumor with macrophages sharing markers or expressing atypical markers. Macrophages, and more particularly those of the M1 type, are the cells most commonly described to be able to produce IL-1β under several stimuli, as their differentiation in vitro is induced by macrophage colony-stimulating factor (M-CSF), LPS, and IFNγ \[[@B137-cancers-12-01791]\].

IL-1β produced at the tumor site can induce macrophage chemotaxis. This was demonstrated in vitro with human metastatic melanoma samples and human cell lines \[[@B66-cancers-12-01791]\], and in vivo in 3-methylcholanthrene (3-MCA)-induced skin cancer \[[@B68-cancers-12-01791]\]. As shown in vitro with human gastric cancer cell lines, IL-1β increases macrophage recruitment by allowing monocyte chemoattractant protein (MCP)-1 expression by tumor cells \[[@B138-cancers-12-01791]\].

Tumor cells can facilitate TAM-mediated IL-1β production. This was suggested by the fact that PDAC cell debris can stimulate IL-1β production by M2-polarized macrophages in vitro \[[@B139-cancers-12-01791]\]. The sphingolipid sphingosine-1-phosphate (S1P), highly expressed by cancer cells, is able to trigger NLRP3 expression in macrophages and subsequent IL-1β production. This pathway plays a major role in tumor lymphangiogenesis, murine lymph node, and lung metastasis, while NLRP3 expression is correlated with human mammary carcinoma development \[[@B140-cancers-12-01791],[@B141-cancers-12-01791]\]. Similarly, murine 4T1 breast cancer cells release soluble CD44, which in turn induces macrophage-mediated IL-1β production, leading to tumor growth and lung metastases \[[@B142-cancers-12-01791]\]. Human lung cancer cells release microparticles that bind TLR3 to trigger NLRP3 inflammasome pathways in macrophages and IL-1β secretion. Thus, macrophages exposed to tumors may become inflammatory TAMs to promote human lung cancer development \[[@B143-cancers-12-01791]\]. Moreover, PDAC cell exosomes alter macrophage phenotype and trigger inflammatory cytokine production, among which is IL-1β \[[@B144-cancers-12-01791]\].

IL-1β derived from TAMs suppresses the expression of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), an enzyme involved in prostaglandin degradation in PDAC cells, which results in tumor growth and poor prognosis for PDAC patients \[[@B145-cancers-12-01791]\]. It can also increase COX-2 expression in human breast cancer cells, thus contributing to cancer progression \[[@B146-cancers-12-01791]\]. In colon cancer, macrophage-derived IL-1β activates NF-κB-dependent PDK1/AKT signaling in tumor cells. This activates the Wnt pathway to enhance tumor growth \[[@B8-cancers-12-01791],[@B147-cancers-12-01791]\]. In parallel, Wnt secretion by p53-deficient breast cancer cells activates IL-1β production by macrophages. IL-1β then activates neutrophils to dampen CD8-mediated anti-tumor immune response \[[@B122-cancers-12-01791]\]. Finally, PDAC cells release ASC, which is able to act as an alarmin and induce IL-1β release by macrophages. Then, this IL-1β is able to trigger CAFs to release thymic stromal lymphopoietin (TSLP), which is a key cytokine for Th2 pro-tumor immune response \[[@B148-cancers-12-01791]\].

Other factors can influence TAM polarization and inflammation. In a non-alcoholic fatty liver disease (NAFLD) model with colon cancer splenic xenograft, a high-fat diet induced TAM M2 polarization and substantial IL-1β and vascular endothelial growth factor (VEGF) production in an NLR family CARD containing 4 (NLRC4)-dependent manner. These events lead to increased liver metastasis, which can be countered using IL-1RA \[[@B149-cancers-12-01791]\]. A high cholesterol diet is also responsible for macrophage production of IL-1β, through NLRP3 activation, and tumor growth in azoxymethane-induced colon cancer \[[@B150-cancers-12-01791]\]. In the same context, obesity can be responsible for the pathogenesis of breast cancer. Human and murine breast tissue-associated adipocytes secrete C-C motif chemokine ligand 2 (CCL2) and IL-1β, which will both recruit and activate macrophages. These recruited cells secrete CXCL12, which is responsible for stromal vascularization and angiogenesis even before cancer occurrence \[[@B151-cancers-12-01791]\]. Finally, in the lung, commensal bacteria stimulate Myd88-dependent IL-1β and IL-23 production from resident macrophages, inducing proliferation and activation of γδ T-cells that produce effector molecules (e.g., IL-17) to promote inflammation and tumor cell proliferation \[[@B152-cancers-12-01791]\].

### 3.2.3. Dendritic Cells {#sec3dot2dot3-cancers-12-01791}

Dendritic cells (DCs) belong to the myeloid lineage. As the principle antigen-presenting cells of the immune system, DCs are immune sentinels and initiate T-cell response against microbial pathogens, tumors, and inflammation \[[@B153-cancers-12-01791],[@B154-cancers-12-01791]\]. The use of DCs as cellular vaccines for immunotherapy has been studied for a long time. It consists in differentiating monocytes into DCs in vitro (with GM-CSF and IL-4). Many studies have tested the addition of a cytokine cocktail to improve DC maturation and activation. These cocktails are generally composed of IL-1β with IL-6, TNFα, and prostaglandin E2 (PGE2) \[[@B155-cancers-12-01791],[@B156-cancers-12-01791]\].

Cancer cell-derived DAMPs (danger-associated molecular patterns) \[[@B157-cancers-12-01791]\], double-stranded oligodeoxynucleotides \[[@B158-cancers-12-01791]\], or bacteria \[[@B159-cancers-12-01791],[@B160-cancers-12-01791]\] can be used to activate TLRs and the inflammasome to enable DCs to release IL-1β. For example, *Salmonella typhimurium* i.v. injected into mice can enable DCs to produce IL-1β and enhance inhibition of colon cancer growth. Inhibiting IL-1β restores tumor growth, while local administration of recombinant IL-1β inhibits tumor growth \[[@B159-cancers-12-01791],[@B160-cancers-12-01791]\].

More physiologically, TMEM176B (transmembrane protein 176B, an immunoregulatory cation channel) has been identified as a new regulator of IL-1β production. In tumor-bearing mice, its deficiency leads to increased activation of caspase-1 and IL-1β production by DCs. In this context, IL-1β enhanced CD4^+^TCRβ^+^RORγt^+^ cells producing IL-17, which are responsible for slowing down tumor growth \[[@B161-cancers-12-01791]\].

### 3.2.4. Neutrophils {#sec3dot2dot4-cancers-12-01791}

Neutrophils originate from myeloid precursors. Because of their phenotypic heterogeneity and functional versatility, neutrophils play a pivotal role in chronic inflammatory diseases, including cancer. Like macrophages, they can have anti- and pro-tumor functions in the tumor microenvironment \[[@B162-cancers-12-01791]\]. Moreover, mature neutrophils share similar morphology and expression of cell surface markers with PMN-MDSCs, but the difference between these cell types relies on the suppression capacity of T-lymphocytes by PMN-MDSCs \[[@B163-cancers-12-01791]\].

In an azoxymethane (AOM)/ dextran sodium sulfate (DSS)-induced cancer-associated colitis model, complement deficiency was shown to inhibit intestinal IL-1β production by neutrophils and IL-17A production by myeloid cells, and to repress tumor formation \[[@B164-cancers-12-01791]\]. As shown in the 3-methylcholanthrene (3-MCA)-induced skin cancer model, IL-1β-deficient animals have fewer intra-tumor neutrophils, while IL-1RA-deficient mice have dense infiltrate, suggesting that IL-1β produced in tumors can recruit neutrophils \[[@B68-cancers-12-01791]\].

However, the signaling of IL-1β in neutrophils can lead to opposite effects. In p53^-/-^ breast cancers, IL-1β-activated neutrophils curb CD8-mediated anti-tumor immune response \[[@B122-cancers-12-01791]\]. In Epstein--Barr virus (EBV)-associated nasopharyngeal carcinoma, viral DNA and intra-tumor DAMPs stimulate inflammasomes to produce IL-1β. This low-level IL-1β favors tumor growth. On the contrary, treatment by irradiation or cisplatin increases tumor cell production of IL-1β, which recruits neutrophils. These tumor-associated neutrophils inhibit tumor growth \[[@B26-cancers-12-01791]\]. In colorectal cancer, IL-1β may improve the control of local microbiota populations by neutrophils. This leads to a selection of microbe species, thus avoiding excessive pro-tumorigenic inflammatory cytokine production \[[@B70-cancers-12-01791]\].

### 3.2.5. T Lymphocytes {#sec3dot2dot5-cancers-12-01791}

The adaptive immune response to cancer is regulated by T lymphocytes \[[@B165-cancers-12-01791]\]. However, tumor-infiltrating CD4^+^ and CD8^+^ T-cells are associated with varying patient survival and clinical outcomes in many types of cancer such as breast \[[@B166-cancers-12-01791]\], colorectal \[[@B167-cancers-12-01791]\], and lung cancers \[[@B168-cancers-12-01791]\]. CD4^+^ T-cell differentiation and CD8^+^ T-cell activation can be modulated by a cytokine network \[[@B169-cancers-12-01791]\]. Among these cytokines is IL-1β.

Using a tetracycline-regulated human *IL1B* transgene in the mouse prostate, it was shown that IL-1β is able to induce the recruitment of CD4^+^ T-cells in inflammatory areas \[[@B170-cancers-12-01791]\]. However, IL-1β has opposing effects on lymphocytes. One hypothesis to explain these discrepancies is the kinetics, frequency, and quantity of IL-1β. In different tumor models, it was shown that IL-1β injection may or may not decrease tumor growth, depending on the setting of the experiment. Injecting too early, or a single injection of IL-1β, has no effect on tumor growth, while several injections and higher doses (10 µg) inhibit tumor growth \[[@B171-cancers-12-01791]\]. When these experiments are performed in immunodeficient mice, IL-1β has no effect, suggesting that T-cells participate in IL-1β-mediated effects.

This gives rise to the second possible explanation for the divergent effects of IL-1β; that is, perhaps it relies on the T cell subtypes present in the tumor. IL-1β seems to be required for secretion of Th1-derived cytokines IL-2 and IFN-γ at the tumor site, and subsequent blockade of B-cell myeloma and lymphoma growth \[[@B172-cancers-12-01791]\]. The importance of IL-1β was confirmed by invalidating IL-1R1 in T-cells (it also inhibits IL-1α signaling). Thus, IL-1R1 signaling in T-cells entails Rorc expression and IL-17A and IL-22 production (suggesting a contribution of Th17 or innate lymphoid cells) and colon cancer progression \[[@B70-cancers-12-01791],[@B173-cancers-12-01791],[@B174-cancers-12-01791]\]. Moreover, cancer cells and APCs from human ovarian cancer samples produce IL-1β, which favors the differentiation and expansion of Th17 cells \[[@B175-cancers-12-01791]\]. Indirectly, IL-1β influences the fate of Treg cells. When produced by CAFs, it favors CCL22 production by tumor cells. CCL22 in turn allows recruitment and polarization of Tregs (through C-C motif chemokine receptor 4 (CCR4)-mediated forkhead box P3 (FOXP3) induction), responsible for the inhibition of the T-cell antitumor effect \[[@B176-cancers-12-01791]\]. On the contrary, IL-1β induces IRF1 expression through STAT1, which then enables enhanced production of IL-9 and IL-21 in CD4 T-cells differentiated into Th9 cells. Th9 cells were shown to have anti-tumor properties. Consequently, Th9 cells generated in the presence of IL-1β exert more marked tumor inhibitory functions \[[@B177-cancers-12-01791]\].

Tumor-derived IL1β activates γδT-cells to produce IL-17. Increased IL-17 levels lead to neutrophil expansion and alteration of their phenotype. These phenotypically altered neutrophils produce inducible nitric oxide synthase (iNOS), which inhibits the activity of anti-tumor CD8^+^ T-cells, resulting in an increase in the capacity of cancer cells to form metastases \[[@B178-cancers-12-01791]\].

IL-1β was shown to have an effect on CD8^+^ T-cells. First, CD137L-mediated DC maturation leads to them producing IL-1β. Then, this cytokine leads to maturation of CD8^+^ T-cells, namely by increasing IFNγ and granzym B production \[[@B179-cancers-12-01791],[@B180-cancers-12-01791]\]. Moreover, CD137L-maturated DC can also polarize CD8^+^ T-cells into Tc1 cells with less expression of exhaustion markers (CTLA-4, TIM-3, PD-1), but without showing the real impact of IL-1β in this phenotype modification \[[@B179-cancers-12-01791]\]. In another study, IL-1β was shown to increase the proportion and functionality of adoptively transferred T-cells in the tumor and to lead to the inhibition of B16 melanoma tumor growth in mice. In this context, IL-1β increases trafficking and survival in peripheral tissues (lymph nodes, liver) and acts indirectly, through IL-15-dependent induction of Granzyme B production \[[@B181-cancers-12-01791]\]. The effects of IL-1β on CD8^+^ T-cells should be further explored to define its mechanism of action and the molecular consequences on CD8^+^ phenotype, activity, and exhaustion.

IL-1β has different effects on immune cells. Thus, its pro- or anti-tumor effect may rely on the type and frequency of immune cells in the tumor.

3.3. Effects of IL-1β on Angiogenesis {#sec3dot3-cancers-12-01791}
-------------------------------------

Angiogenesis is a process that enables the formation of new blood vessels to support the growth of malignant tumors by supplying oxygen and nutrients to cancer cells \[[@B182-cancers-12-01791]\]. This phenomenon is induced by HIF, which promotes oncogene activation, pro-angiogenic factor expression, and anti-angiogenic factor suppression. The most important pro-angiogenic factors are vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factors (FGF) \[[@B183-cancers-12-01791]\]. However, IL-1β is also an important regulator of angiogenesis.

In vitro, human samples (metastatic melanoma) and human cell lines (melanoma, oral squamous cell carcinoma (OSCC)) have been shown to produce IL-1β, which favors tube formation by HUVEC cells \[[@B66-cancers-12-01791],[@B89-cancers-12-01791]\].

The impact of IL-1β on angiogenesis has also been observed in different cancer models. For example, in a transgenic model of Myc-dependent carcinogenesis, IL-1β triggers VEGF production and neo-angiogenesis \[[@B184-cancers-12-01791]\]. Moreover, when experiments are performed in IL-1β-deficient mice or using IL-1RA, the vascularization of the tumor was abrogated \[[@B67-cancers-12-01791],[@B185-cancers-12-01791],[@B186-cancers-12-01791]\]. This pro-angiogenic role was observed even when IL-1β was produced by different cell types, that is, cancer cells or myeloid cells. Fibrosarcoma or Lewis lung carcinoma (LLC) cells modified to constitutively secrete IL-1β were shown in vivo to promote angiogenesis, through the induction of VEGF, CXCL2, and hepatocyte growth factor production by cancer and stromal cells, leading to tumor progression \[[@B68-cancers-12-01791],[@B187-cancers-12-01791],[@B188-cancers-12-01791]\]. In melanoma, production of VEGF and other proangiogenic factors by endothelial cells is dependent on myeloid cell (macrophages or MDSCs)-derived IL-1β \[[@B185-cancers-12-01791],[@B189-cancers-12-01791]\].

In a mouse model with a high fat diet, obesity was shown to drive angiogenesis and cancer progression. Two mechanisms were proposed. Macrophage-derived IL-1β is able to stimulate the production of Angiopoietin-like 4 (ANGPTL4), a pro-angiogenic factor, in adipocytes \[[@B190-cancers-12-01791]\]. NLRC4 inflammasome activation in myeloid cells can trigger the secretion of IL-1β, which in turn stimulates adipocytes to secrete VEGF-A \[[@B191-cancers-12-01791]\].

3.4. Effects of IL-1β on Cancer Metastasis {#sec3dot4-cancers-12-01791}
------------------------------------------

Metastasis is the mechanism leading to the spread of cancer cells from the original site of the tumor to other major organs, such as the lung, liver, and kidney. It proceeds directly through invasion into the adjacent tissues or indirectly through several steps, including intravasation, circulation through blood or lymphatic vessels, anchoring at a secondary site, extravasation, and establishment of metastatic lesions in distant organs \[[@B192-cancers-12-01791]\].

The importance of IL-1β in metastasis was first observed 30 years ago. Injection of IL-1β in mice increased lung and hepatic metastasis \[[@B193-cancers-12-01791],[@B194-cancers-12-01791]\]. Moreover, IL-1β-overexpressing fibrosarcoma cells have an increased invasion potential \[[@B131-cancers-12-01791],[@B195-cancers-12-01791]\]. On the contrary, the invalidation of IL-1β or inflammasome components, responsible for IL-1β maturation, was associated with reduced lung or hepatic metastasis \[[@B196-cancers-12-01791],[@B197-cancers-12-01791]\]. Similar results were observed for breast cancer bone metastasis, using anakinra (IL-1RA) \[[@B198-cancers-12-01791]\]. Moreover, IL-1β silencing decreases metastatic potential of murine prostate cancer cells, while its overexpression increases it \[[@B199-cancers-12-01791]\].

IL-1β is able to regulate metastasis at various levels, for example, by regulating (EMT), cancer cell stemness, sphere formation, or migration/invasion.

EMT is the process responsible for cancer cells acquiring stem-like properties, as well as migratory and invasive capacities. However, inhibition of EMT also induces cancer stemness and mesenchymal--epithelial transition, the reverse process of EMT, which is associated with the tumor-initiating ability required for metastatic colonization \[[@B200-cancers-12-01791]\]. This may explain observations relating to the role of IL-1β on EMT. On one hand, continuous exposure of NSCLC to IL-1β induces the EMT phenotype, with high expression of the transcription factor SLUG required for the establishment of EMT memory. Furthermore, even when IL-1β exposure was withdrawn, cancer cells sustained their acquired phenotype \[[@B115-cancers-12-01791],[@B201-cancers-12-01791]\]. In breast cancer, IL-1β induces BIRC3 expression and estrogen receptor (ER) α gene methylation, leading to EMT \[[@B202-cancers-12-01791],[@B203-cancers-12-01791]\]. IL-1β also stabilizes Snail, an EMT actor, in an NF-κB/AKT/Wnt-dependent manner in human colon cancer cells \[[@B204-cancers-12-01791]\]. Anti-IL-1β antibodies, just like anti-IL-6, attenuated EMT phenotype in breast cancer cells \[[@B80-cancers-12-01791]\]. On the other hand, at the metastatic site, IL-1β maintains cancer cells in a ZEB1-positive differentiation state, preventing their establishment. The absence of inflammation or blocking IL-1R removes the differentiation block and allows metastatic colonization. Among lymph node-positive breast cancer patients, high IL-1β expression in the primary tumor is associated with better overall survival and distant-metastasis-free survival \[[@B205-cancers-12-01791]\]. These discrepancies in IL-1β activity need to be carefully considered when developing anti-IL-1β therapies.

Recombinant IL-1β enhances the sphere-forming capacity of cancer stem cells (CSCs) by increasing stemness gene expression (Bmi1 and Nestin) \[[@B206-cancers-12-01791]\]. Furthermore, carcinoma-derived IL-1 (IL-1α and IL-1β) favors a transition from tumor cells into CSCs \[[@B207-cancers-12-01791]\]. This is because of the capacity of IL-1 to allow mesenchymal stem cells to produce factors (PGE2, IL-6, IL-8, Gro-α, RANTES) that in turn activate β-catenin in cancer cells. β-catenin is a master regulator of proliferation, migration, and invasion \[[@B207-cancers-12-01791]\]. IL-1β can also act directly on gastric cancer cells and induces PI3K activation and translocation of S100A4, a factor known to be involved in the metastasis of several types of cancer \[[@B208-cancers-12-01791],[@B209-cancers-12-01791]\]. Finally, IL-1β-induced β1-integrin expression is responsible for ovarian tumor cell adhesion to mesothelia, a crucial step in ovarian cancer dissemination \[[@B210-cancers-12-01791]\].

The IL-1β responsible for migration/invasion was shown to be produced by cells in the tumor microenvironment, such as macrophages, fibroblasts, and B-cells. In co-cultures of glioblastoma cells with PBMC, anakinra was shown to inhibit inflammatory crosstalk and cancer cell migration \[[@B211-cancers-12-01791]\]. NLRP3 expression in TAMs is correlated with lymph node invasion, metastasis, and survival in mammary carcinoma patients \[[@B140-cancers-12-01791]\]. This was sustained by the fact that inhibition or invalidation of NLRP3 in macrophages inhibited the metastatic potential of B16F10 murine melanoma cells in vitro \[[@B212-cancers-12-01791]\]. Finally, macrophage-derived IL-1β was shown to regulate breast carcinoma cell migration and their adhesion to, and transmigration across, blood and lymphatic endothelial cells \[[@B213-cancers-12-01791]\]. Cancer cells and fibroblasts can interact with each other to regulate cancer cell migration. First, tumor-induced tissue damage can be sensed as a DAMP by CAFs. This allows the activation of the NLRP3 inflammasome, the production of IL-1β, leading to tumor progression and lung metastasis \[[@B214-cancers-12-01791]\]. Another study showed that IL-1β expressed in OSCC cells leads to CXCL1 production by CAFs, which in turn promotes cancer cell migration \[[@B215-cancers-12-01791]\]. Further studies are required to evaluate whether these two pathways can co-exist. B-cells are more easily recruited in renal carcinoma tissues than in normal renal tissues. The interaction between B-cells and cancer cells allows IL-1β secretion, which is responsible for renal cancer cell migration, through HIF-2α and Notch1 pathways \[[@B216-cancers-12-01791]\]. Production of IL-1β by cancer cells or neighboring cells can activate many molecular pathways that lead to cancer cell migration. It activates p38 in gastric cancer \[[@B84-cancers-12-01791],[@B217-cancers-12-01791]\], extracellular signal-regulated protein kinase (ERK)1/2, AP-1, and MMP9 in invasive breast ductal carcinoma \[[@B218-cancers-12-01791]\], and PI3K/Rac 1-regulated reorganization of the actin cytoskeleton of mammary MCF-7 cells \[[@B219-cancers-12-01791]\]. IL-1β also increases TWIST expression in gallbladder cancer \[[@B220-cancers-12-01791]\], and c-MYC, CCDN1, SNAIL1, and MMP2 expression through β-catenin pathway activation \[[@B221-cancers-12-01791]\].

3.5. Pro- and Anti-Tumor Effects of IL-1β during Cancer Treatment {#sec3dot5-cancers-12-01791}
-----------------------------------------------------------------

Beyond regulating cancer appearance or progression, IL-1β can also influence anti-cancer treatments. In fact, chemotherapy and radiation can trigger the production of IL-1β by either cancer cells or tumor infiltrating cells, such as macrophages, DCs, or MDSCs ([Figure 3](#cancers-12-01791-f003){ref-type="fig"}).

Chemotherapeutic agents such as doxorubicin or cisplatin give rise to NLRP3 expression, caspase-1 activation, and pyroptotic cell death of multiple mesothelioma cells. This leads to IL-1β release from cancer cells, and the use of anakinra in combination with cisplatin was shown to achieve decreased tumor growth in mice \[[@B222-cancers-12-01791]\]. On the other hand, in nasopharyngeal carcinoma cells, the inflammasome is activated by cisplatin or radiation, through cathepsin B release from lysosomes or ROS production and mitochondrial DNA release into the cytosol, respectively. In this case, tumor-released IL-1β helps therapeutic treatments to inhibit tumor growth by recruiting neutrophils at the tumor site \[[@B26-cancers-12-01791]\]. Chemoresistant cancer cells can also release IL-1β. This is the case of PDAC cell lines resistant to etoposide or doxorubicin, which constitutively secrete IL-1β, maintaining an NF-κB amplification loop responsible for chemoresistance \[[@B223-cancers-12-01791],[@B224-cancers-12-01791]\]. This observation was confirmed on tumor samples that highly express p65 NF-κB subunit and IL-1β, contrary to normal pancreatic tissues \[[@B225-cancers-12-01791],[@B226-cancers-12-01791]\]. Similarly, radiotherapy-resistant breast cancer cells secrete ATP, which in turn associates with its receptor P2Y2R on the cancer cell surface to induce caspase-1 activation and IL-1β release. Then, IL-1β induces MMP9 expression and invasion \[[@B227-cancers-12-01791]\].

Chemotherapy can have opposing effects on anti-tumor immune response. First, it has been shown that anthracyclines, such as oxaliplatin, can activate NLRP3 inflammasome indirectly in DCs. Indeed, these compounds induce immunogenic cell death of cancer cells that release DAMPs such as ATP. Then, the released ATP associates with its receptor P2RX7 on DCs and induces caspase-1 activation and IL-1β release. The IL-1β thus released activates IFNγ-producing CD8+ T-cells \[[@B228-cancers-12-01791]\]. In this context, the P2RX7/NLRP3 pathway is essential, as the anti-tumor effect of oxaliplatin is lost in mice deficient in these proteins. Moreover, breast cancer patients with a loss-of-function allele of P2RX7 developed more metastases than patients bearing the normal allele \[[@B228-cancers-12-01791]\]. IL-1β inhibitors were also shown to reduce the anti-tumorigenic effect of oxaliplatin or anthracyclines \[[@B229-cancers-12-01791]\]. On the contrary, we showed that other chemotherapies, such as 5-fluorouracil (5-FU) and gemcitabine, directly activate NLRP3 inflammasome in MDSCs, through a cathepsin B-dependent pathway, and enable IL-1β release by these cells. However, in this context, IL-1β targets CD4^+^ T-cells, which then produce IL-17. IL-17 is in turn responsible for neo-angiogenesis and tumor growth \[[@B230-cancers-12-01791]\]. The NLRP3/IL-1β pathway is required for the deleterious effects of 5-FU and gemcitabine on tumor immune response, as tumor growth is inhibited in mice deficient for NLRP3, or IL-1R. Moreover, anakinra in combination with 5-FU inhibits tumor growth in mice and also enables stabilization of disease in refractory metastatic colorectal cancer patients, suggesting that this combination might have promise as a potential treatment \[[@B230-cancers-12-01791],[@B231-cancers-12-01791]\]. We previously showed that HSP70 can inhibit NLRP3 inflammasome \[[@B232-cancers-12-01791],[@B233-cancers-12-01791]\]. The importance of IL-1β in tumor escape from 5-FU treatment was strengthened, with the confirmation that HSP70 deficiency in mice leads to high caspase-1 activation in MDSCs, subsequent angiogenesis, and rapid tumor growth, whereas hyperthermia (which increases HSP70 expression) inhibits these events and slows down tumor growth \[[@B234-cancers-12-01791]\].

Other chemotherapeutic agents have been shown to be capable of inducing IL-1β release from myeloid cells. For example, BRAF inhibitors vemurafenib and dabrafenib were shown to enable IL-1β secretion by human and murine DCs, but the authors did not explain whether this action on IL-1β was pro- or anti-tumor \[[@B114-cancers-12-01791]\]. Paclitaxel favors NLRP3 activation in macrophages \[[@B235-cancers-12-01791],[@B236-cancers-12-01791]\]. In different murine cancer types, this placlitaxel-induced macrophage IL-1β secretion slightly reduced the primary tumor, while promoting metastasis, suggesting a dual role for this drug \[[@B237-cancers-12-01791]\].

These observations suggest that IL-1β may alternatively favor or inhibit chemotherapy-mediated anti-tumor immune response. Thus, the association of IL-1β or anti-IL-1β with chemotherapy should be considered, according to the drugs used.

4. Therapeutic Perspectives {#sec4-cancers-12-01791}
===========================

We have seen that IL-1β is generally a promoter of cancer by acting on cancer cell proliferation and invasion, neo-angiogenesis, or tumor infiltrating immune cells. However, depending on the cancer type or stage, the main type of immune cells present in the tumor microenvironment, and the anti-cancer treatment used, inhibiting IL-1β may or may not be beneficial for patients.

IL-1β can be blocked at different levels: IL-1β itself, using antibodies, or IL-1β maturation, using inhibitors of inflammasomes, or inhibitors of the pathways leading to their activation.

Many antibodies have been developed to block IL-1β. The IL-1RA anakinra is one of the most widely used in pre-clinical studies. Anakinra is a non-glycosylated form of human IL-1RA that competitively inhibits IL-1α and IL-1β from binding to their receptor \[[@B238-cancers-12-01791]\]. It has shown benefits in several clinical trials. Anakinra decreased the myeloma proliferative rate of smoldering or indolent multiple myeloma, leading to a chronic disease state and improved PFS \[[@B239-cancers-12-01791]\]. In a phase II clinical study, we showed that using anakinra restored antitumor efficacy of 5-FU in heavily pretreated patients. Of the 32 patients enrolled, 5 showed a response (CHOI criteria) and 22 patients had stable disease \[[@B231-cancers-12-01791]\]. Anakinra is currently being tested in further clinical trials. Another possible candidate is rilonacept, the extracellular domain of the IL-1RAcP and the IL-1R1 fused to the Fc portion of human IgG1. It has high affinity with IL-1β and IL-1α and potently inhibits IL-1 activity \[[@B240-cancers-12-01791]\]. However, these blockers inhibit both IL-1β and IL-1α, but IL-1α can have tumor promoting or inhibiting functions, and inhibiting this isoform together with IL-1β can have synergistic or antagonist effects, depending on the context.

Canakinumab is a specific human monoclonal IgG1 antibody that targets IL-1β. This antibody has no cross-reactivity with either IL-1α or IL-1R1 \[[@B240-cancers-12-01791]\]. A recent phase three clinical trial (CANTOS) involving 10,500 patients demonstrated that canakinumab could significantly reduce lung cancer incidence and patient mortality. However, fatal infections and sepsis were more common in the canakinumab group than in the placebo group \[[@B241-cancers-12-01791]\]. Another mAb that inhibits IL-1β, gevokizumab, used in inflammatory disorders, could also be proposed in cancer treatment \[[@B242-cancers-12-01791]\].

Several inflammasome chemical inhibitors tested in vivo and in vitro, such as MCC950, CY09, OLT1177, oridonin (targeting NLRP3 ATPase), or tranilast (targeting NLRP3 oligomerization), should be considered \[[@B243-cancers-12-01791]\]. MCC950 was shown to successfully inhibit inflammation and to improve murine ulcerative colitis \[[@B244-cancers-12-01791]\]. Specific caspase-1 inhibitors including ritonavir and VX-740/765 are also of interest. Ritonavir was originally developed for the treatment of HIV \[[@B245-cancers-12-01791]\]. VX-765 is well tolerated and has shown benefits in a mouse model of rheumatoid arthritis \[[@B246-cancers-12-01791]\]. Finally, we proposed hyperthermia as a new modulator of the NLRP3 inflammasome \[[@B232-cancers-12-01791]\]. It can block caspase-1 activation in MDSCs, and subsequent angiogenesis and rapid tumor growth in mice \[[@B234-cancers-12-01791]\]. Although hyperthermia is already used in specific treatment protocols, further studies are required to demonstrate its efficiency in humans. However, blocking inflammasomes may have limitations such as off-target effects, by inhibiting maturation of IL-18, an anti-tumor cytokine.

Another way to inhibit inflammasomes is to target molecular pathways leading to their activation. Thus, ion efflux (K^+^, Ca^2+^, Cl^−^), ROS or oxidized mitochondrial DNA generation, and lysosomal destabilization/cathepsin B can be targeted \[[@B247-cancers-12-01791]\]. Potassium efflux can be inhibited by glyburide, a compound tested in gestational diabetes mellitus \[[@B248-cancers-12-01791]\] or by P2RX7 inhibitors (oxATP, AZ10606120), which have shown anti-tumor effects in the murine B16 melanoma model \[[@B249-cancers-12-01791]\]. ROS production can be dampened by antioxidants, which have shown health benefits when added to the diet. However, blocking one of these pathways requires adequate knowledge of its implication in cancer progression or resistance to treatment.

5. Conclusions {#sec5-cancers-12-01791}
==============

To conclude, we have highlighted in this review the pleiotropic effects of IL-1β in cancer. Although its role is primarily pro-tumoral, some examples have shown that it may also contribute to anti-tumor immune response. The exact explanations for these opposing effects are not yet known. The level of IL-1β produced, the type of producing cells, the microenvironment (immune cells or fibroblasts), the stage of the cancer, and the anti-cancer treatments used may all participate in the divergent effects of IL-1β. Further studies are required to elucidate these points. In any case, the use IL-1β blockers in the clinical context should be carefully considered, in order to guarantee the best treatment for patients.
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![Different steps of interleukin (IL)-1β production and signaling: priming, NOD-LRR and pyrin containing protein 3 (NLRP3) inflammasome activation, secretion, and signaling. LPS, lipopolysaccharides; TLR, toll-like-receptor; TNF, tumor necrosis factor; TNFR, TNF receptor; TRADD, TNFR1-associated death domain; RIP, receptor interacting protein; IRAK, interleukin-1 receptor-associated kinase; Myd, myeloid differentiation primary response; TRAF, TNFR-associated factor; ASC, apoptosis associated speck-like protein containing a CARD domain; GSDMD, gasdermin D; ROS, reactive oxygen species; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B-cells.](cancers-12-01791-g001){#cancers-12-01791-f001}

![IL-1β effects on pro- and anti-tumor immune response. TSLP, thymic stromal lymphopoietin; CAF, cancer-associated fibroblast; PGDH, hydroxyprostaglandin dehydrogenase; MDSC, myeloid-derived suppressor cells; PMN, polymorphonuclear; COX, cyclooxygenase; DAMPs, danger-associated molecular patterns; CCL, C-C motif chemokine ligand; IFN, interferon; NK, natural killer.](cancers-12-01791-g002){#cancers-12-01791-f002}
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Effects of interleukin (IL)-1β or IL1B expression or IL1B polymorphisms on cancer. NSCLC, non-small cell lung cancer.

  Heading                                    Type of Cancer             Pro (+) or Anti (−) Tumor                                                                                                                                                                                                     Ref.
  ------------------------------------------ -------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------
  High IL-1β IHC staining                    Nasopharyngeal carcinoma   (−)                                                                                                                                                                                                                           \[[@B26-cancers-12-01791]\]
  High IL-1β blood level                     NSCLC                      (+)                                                                                                                                                                                                                           \[[@B27-cancers-12-01791],[@B28-cancers-12-01791],[@B29-cancers-12-01791]\]
  High IL1B mRNA                             Breast cancer              (−)                                                                                                                                                                                                                           \[[@B30-cancers-12-01791]\]
  High IL1B mRNA                             Cervical cancer            (−)                                                                                                                                                                                                                           \[[@B31-cancers-12-01791]\]
  High IL1B-signature                        Gliomas                    (+)                                                                                                                                                                                                                           \[[@B32-cancers-12-01791]\]
  *IL1B-511 C \> T* (rs16944) T allele       Ovarian cancer             (+) or (−)                                                                                                                                                                                                                    \[[@B33-cancers-12-01791],[@B34-cancers-12-01791],[@B35-cancers-12-01791]\]
  Lung cancer                                (+) or (−)                 \[[@B36-cancers-12-01791],[@B37-cancers-12-01791]\]                                                                                                                                                                           
  Gastric cancer                             (+) or (−)                 \[[@B38-cancers-12-01791],[@B39-cancers-12-01791],[@B40-cancers-12-01791],[@B41-cancers-12-01791],[@B42-cancers-12-01791],[@B43-cancers-12-01791],[@B44-cancers-12-01791],[@B45-cancers-12-01791],[@B46-cancers-12-01791]\]   
  Cervical cancer                            (+)                        \[[@B47-cancers-12-01791],[@B48-cancers-12-01791]\]                                                                                                                                                                           
  Acute myeloid leukemia                     (+)                        \[[@B49-cancers-12-01791]\]                                                                                                                                                                                                   
  Chronic myeloid leukemia                   (+)                        \[[@B50-cancers-12-01791]\]                                                                                                                                                                                                   
  *IL-1β-31 C \> T* (rs1143627) T allele     Breast cancer              (+)                                                                                                                                                                                                                           \[[@B51-cancers-12-01791],[@B52-cancers-12-01791]\]
  Lung cancer                                (+)                        \[[@B36-cancers-12-01791],[@B37-cancers-12-01791]\]                                                                                                                                                                           
  Cervical cancer                            (+)                        \[[@B48-cancers-12-01791]\]                                                                                                                                                                                                   
  Hepatocellular carcinoma                   (+)                        \[[@B53-cancers-12-01791]\]                                                                                                                                                                                                   
  Osteosarcoma                               (+)                        \[[@B54-cancers-12-01791]\]                                                                                                                                                                                                   
  *IL-1β-31 C \> T* (rs1143627) C allele     Gastric cancer             (+)                                                                                                                                                                                                                           \[[@B45-cancers-12-01791]\]
  *IL-1β-1464 G \> C* (rs1143623) G allele   Renal cell carcinoma       (+)                                                                                                                                                                                                                           \[[@B55-cancers-12-01791]\]
